Psych Vivas · Consultation-liaison psychiatry
Multiple sclerosis psychiatry — structured clinical viva
Fellowship viva on MS depression, PBA, suicide, cognition, and DMT interface.
On this page & tools
Target exams
Interpretation
Reveal interpretation
Leading diagnoses: MS-associated major depression with suicide risk plus probable PBA (brief involuntary crying without sadness) plus cognitive complaints with vocational threat; interferon–mood link is possible contributor but usually multifactorial.[1][5]
Differentials to voice: demoralisation only; bipolar spectrum; steroid effects if recent pulses; delirium; pure fatigue mislabelled as depression; primary anxiety; cognitive impairment independent of mood (Rao patterns).[2][6]
Plan: explicit suicide assessment; CBT (telephone-capable); SSRI with monitoring; PBA education and DM/Q if available (QT/interactions) or pragmatic SSRI; cognitive screening/neuropsychology; do not stop DMT unilaterally — joint neurology decision.[2][3][4][7]
Close: shared MS–psychiatry follow-up, partner education, work supports, crisis plan.[1][5]
Key points
References
- [1]Goldman Consensus Group The Goldman Consensus statement on depression in multiple sclerosis Mult Scler, 2005.PMID 15957516
- [2]Minden SL, Feinstein A, Kalb RC, et al. Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS Neurology, 2014.PMID 24376275
- [3]Pioro EP, Brooks BR, Cummings J, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect Ann Neurol, 2010.PMID 20839238
- [4]Mohr DC, Hart SL, Julian L, et al. Telephone-administered psychotherapy for depression Arch Gen Psychiatry, 2005.PMID 16143732
- [5]Feinstein A, Pavisian B Multiple sclerosis and suicide Mult Scler, 2017.PMID 28327056
- [6]Rao SM, Leo GJ, Bernardin L, Unverzagt F Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction Neurology, 1991.PMID 2027484
- [7]Patten SB, Williams JV, Metz LM Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis Mult Scler, 2008.PMID 17986504